2CUREX AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.364 SEK | -18.39% |
|
-7.85% | -81.89% |
| Feb. 29 | 2curex AB Elects Grith Hagel as a New Board Member | CI |
| Feb. 22 | 2cureX AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -81.89% | 586K | |
| -20.55% | 10.81B | |
| +47.97% | 3.36B | |
| -32.75% | 2.22B | |
| -14.15% | 2.16B | |
| -26.06% | 1.55B | |
| +19.85% | 1.04B | |
| -2.62% | 746M | |
| -31.67% | 425M | |
| -43.88% | 405M |
- Stock Market
- Equities
- 2CUREX Stock
- News 2cureX AB
- 2cureX Makes Executive Changes Amid Planned Global Expansion of IndiTreat Tests; Shares Drop
